EcoDrugPlus

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSMAMG00000003875
Gene Symbol: RELA
3 Cross references
199 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSMAMG00000005314
Gene Symbol: SRC
3 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSMAMG00000006341
Gene Symbol: VEGFAA
2 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSMAMG00000028040
Gene Symbol: VEGFAB
3 Cross references
201 Possible Orthologues:

Vasopressin V2 Receptor-Like

Ensembl ID : ENSMAMG00000006448
Gene Symbol: LOC113145571
2 Cross references
148 Possible Orthologues:

Vitamin D3 Receptor A

Ensembl ID : ENSMAMG00000007869
Gene Symbol: LOC113145819
2 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSMAMG00000016835
Gene Symbol: LOC113129971
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSMAMG00000012297
Gene Symbol: VKORC1
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSMAMG00000021521
Gene Symbol: LOC113127256
2 Cross references
69 Possible Orthologues:

Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1e-Like

Ensembl ID : ENSMAMG00000004395
Gene Symbol: LOC113129348
2 Cross references
213 Possible Orthologues:

Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1e-Like

Ensembl ID : ENSMAMG00000015076
Gene Symbol: LOC113133847
2 Cross references
207 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1g-Like

Ensembl ID : ENSMAMG00000027582
Gene Symbol: LOC113128008
2 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).